Skip to main content
SpringerLink
Log in

Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Aim. The study evaluates the therapeutic efficacy of Strontium‐89‐chloride (89Sr) and 186Re‐1,1‐hydroxy‐ethylidene diphosphonate (186Re‐HEDP) in the palliation of painful bone metastases from breast cancer.

Patients and methods. Fifty patients with painful multifocal bone metastases from breast cancer entered the study and were randomized into two groups according to the radiopharmaceutical used: 148 MBq 89Sr i.v. (Group A: 25 patients) and 1406 MBq 186Re‐HEDP i.v. (Group B: 25 patients). Pain palliation was evaluated on the basis of the Wisconsin pain test improvement at two months and response was graded as complete, partial, minimal or absent. Hematological toxicity and side effects were reported according to WHO guidelines.

Results. The global response rate was 84% (21/25) for 89Sr and 92% (23/25) for 186Re‐HEDP, respectively. The onset of pain palliation appeared significantly earlier in Group B (p<0.0001). The duration of pain relief ranged from two months to 14 months (mean of 125 days with a median value of 120 days) in Group A and from one month to 12 months (mean of 107 days with a median value of 60 days) in Group B (p=0.39). A moderate hematological toxicity was apparent in both groups. Platelet and white blood cell counts returned to baseline levels within 12 weeks after 89Sr administration and 6 weeks after 186Re‐HEDP administration (p<0.01).

Conclusions. Both 89Sr and 186Re‐HEDP are effective and safe in bone pain palliation in breast cancer with the latter showing a significantly faster onset of pain relief.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997

    Google Scholar 

  2. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-6, 1987

    Google Scholar 

  3. Gilbert HA, Kagan AR, Nussbaum H, Rao AR, Satzman J, Chan P, Allen B, Forsythe A: Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol 129: 1095-1096, 1977

    Google Scholar 

  4. Nielsen OS, Munro AJ, Tannock IF: Bone metastases: pathophisiology and management policy. J Clin Oncol 9: 509-524, 1991

    Google Scholar 

  5. Hoskin PJ, Ford HT, Harmer CL: Hemibody irradiation for metastatic bone pain in two histologically distinct groups of patients. Clin Oncol 1: 67-69, 1989

    Google Scholar 

  6. Silberstein EB, Williams C: Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26: 345-348, 1985

    Google Scholar 

  7. Robinson RG, Preston DF, Schiefelbein M, Baxter BG: Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 274: 420-424, 1995

    Google Scholar 

  8. Kloiber R, Molnar CP, Barnes M: Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up. Radiology 163: 719-723, 1987

    Google Scholar 

  9. Dearnley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM, Lewington VL: Palliation of bone metastases in prostate cancer: hemibody irradiation or strontium-89. Clin Oncol 4: 101-107, 1992

    Google Scholar 

  10. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG, Broccatelli M: Radiosensitization with low-dose carboplat in enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 17: 799-804, 1996

    Google Scholar 

  11. Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Moulton JS, Williams CC, Ehrhardt GJ: Rhenium-186 (Sn) HEDP for treatment of painful osseous metastases: results of a double blind comparison with placebo. J Nucl Med 32: 1877-1881, 1991

    Google Scholar 

  12. de Klerk JMH, Zonnemberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP: Dose escalation study of rhenium-186-hydroxyethilidene diphosphonate in patient with metastatic prostate cancer. Eur J Nucl Med 21: 1114-1120, 1994

    Google Scholar 

  13. Maxon HR, Schroder LE, Thomas SR, Hertzeberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS, Schneider HJ: Re-186(Sn)-HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176: 155-159, 1990

    Google Scholar 

  14. Quirijnen MSP, Han SH, Zonnenberg BA, de Klerk JMH, van het Schip AD, van Dijk A, ten Kroode HFJ, Blijham GH, van Rijk PP: Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 37: 1511-1515, 1996

    Google Scholar 

  15. Berna L, Carrio I, Alonso C, Ferrè J, Estorch M, Torres G: Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 22: 1101-1104, 1995

    Google Scholar 

  16. Robinson RG, Prestin DF, Baxter KG, Dusing RW, Spicer JA: Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 20: 44-48, 1993

    Google Scholar 

  17. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D: Strontium-89 for palliation of pa in from bone metastases in patients with cancer. Eur J Nucl Med 24: 1210-1214, 1997

    Google Scholar 

  18. Pizzoccaro C, Panarotto MB, De Agostini A, Pagliaini R, Bestagno M: Experience with 89-strontium treatment of painful osseous metastases from breast cancer. Tumori 83: 558-559, 1997

    Google Scholar 

  19. Baziotis N, Yakoumakis E, Zissimopoulos A, Geronicola-Trapali X, Malamitsi J, Proukakis CH: Strontium-89-chloride in the treatment of bone metastases from breast cancer. Oncology 55: 377-381, 1998

    Google Scholar 

  20. Virotta G, Medolago G, Arrigoni S, Butti I, Bertocchi C: Rhenium-186-hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma. Tumori 83: 563-565, 1997

    Google Scholar 

  21. Han SH, Zonnenberg BA, de Klerk JMH, Quirijnen JMSP, van het Schip AD, van Dijk A, Blijam GH, van Rijk PP: 186 Re-Etidronatein breast cancer patients with metastatic bone pain. J Nucl Med 40: 639-642, 1999

    Google Scholar 

  22. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988

    Google Scholar 

  23. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no 48, Geneve, 1979

  24. Mac Ewan AJ: Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 27: 165-182, 1997

    Google Scholar 

  25. Motulsky H: Intuitive Biostatistics. Oxford University Press, New York, 1995

    Google Scholar 

  26. Riffenburgh RH: Statistics in Medicine. Academic Press, San Diego, 1999

    Google Scholar 

  27. Samaratunga RC, Thomas SR, Hinnefeld JD, von Kuster LC, Hyams DM, Moulton JS, Matthew I, Sperling MI, Maxon III HR: A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from Rhenium-186(Sn)-HEDP. J Nucl Med 36: 336-350, 1995

    Google Scholar 

  28. Kasalicky J, Krajskà V: The effect of repeated strontium-89 chloride therapy on bone pa in palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25: 1362-1367, 1998

    Google Scholar 

  29. de Klerk JMH, Zonnenberg BA, Geert HB, van het Schip AD, Hoekstra A, Han SH, Quirijnen HMSP, van Dijk A, van Rijk PP: Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res 17: 1773-1778, 1997

    Google Scholar 

  30. Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini CL: Short and long term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41: 647-654, 2000

    Google Scholar 

  31. Mauch PM: Treatment of metastatic cancer to bone. In: DeVita VT, Jr, Hellman S, Rosenberg SA (eds) Cancer. Principles and Practice of oncology. JB Lippincott, Philadelphia, 1993, pp 1564-1579

    Google Scholar 

  32. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM: Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29: 549-557, 1988

    Google Scholar 

  33. Maxon HR, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC, Ali S: Re-186(Sn)HEDP for treatment of multiple metastatic foci, in bone: human biodistribution and dosimetric studies. Radiology 166: 501-507, 1988

    Google Scholar 

  34. Mertens WC, Porter AT, Reid RH, Powe J. Strontium-89 and low-dose infusion cisplat in for patient with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 33: 1437-1443, 1992

    Google Scholar 

  35. Paulus P: 186Re-HEDP in routine use: correlation between dose rate measurement and clinical efficacy. In: ‘The Update 186Re-HEDP’. Mallinckrodt, 1995, pp 17-20

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Regina Elena Cancer Institute, Rome, Italy

    Rosa Sciuto, Anna Festa, Rosella Pasqualoni, Alessandro Semprebene, Sandra Rea, Serenella Bergomi & Carlo L. Maini

Authors
  1. Rosa Sciuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Festa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosella Pasqualoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Semprebene
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sandra Rea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Serenella Bergomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carlo L. Maini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sciuto, R., Festa, A., Pasqualoni, R. et al. Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients. Breast Cancer Res Treat 66, 101–109 (2001). https://doi.org/10.1023/A:1010658522847

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010658522847

Search

Navigation